French Innovative Leukemia Organisation

This study tests whether giving the drug venetoclax early can help people with a slow-growing but high-risk form of chronic lymphocytic leukemia (CLL). About 82 participants with early-stage CLL who have certain risk factors will receive venetoclax. The main goal is to see how ma…

This study looks at whether older, frail patients with untreated chronic lymphocytic leukemia (CLL) can safely stop taking the targeted drug acalabrutinib after 18 months and then restart it only if their disease comes back. The goal is to reduce long-term side effects and lower …

This study tests a combination of two drugs, ibrutinib and daratumumab, in people with a hard-to-treat form of chronic lymphocytic leukemia (CLL) that has come back or not responded to prior treatment. The focus is on patients with a specific genetic problem (p53 dysfunction) tha…

This study follows 1,000 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. Researchers will observe which therapies doctors choose in everyday practice and how different treatment sequences affect long-term survival and side ef…